Executive Resources
How Board Members & Directors Can Avoid Liability Risks
A Roadmap to Avoiding Board & Director Liability Risks
Year: 2018
Capital
Investor Education
Sustaining Income Throughout Retirement
Retirement Income Strategies
Executive Resources
CEO Interview
Clean Coal Technologies (OTC: CCTC) “Game Changer” technology for the $50 billion coal market?
Clean Coal Technologies (OTC: CCTC) Interview with CEO Robin Eves, and COO Aiden Neary discussing progress in commercializing the company’s “game changer” disruptive technology for the global […]
Consumer
Aurora Cannabis (TSX: ACB) Investor Presentation
Aurora Cannabis (TSX: ACB) (OTC: ACBFF) Investor Presentation by Cam Battley, EVP
Capital
Grant Cardone on Money
Grant Cardone on Money
Currencies
Forex Trading for Black Swan Events
Jack Crooks: Black Swan Foreign Currency Trading
CEO Interview
Village Farms International (TSX: VFF:) CEO Michael DeGiglio discusses expansion into cannabis market.
Village Farms International (TSX: VFF:) CEO Michael DeGiglio discusses the greenhouse growing company’s expansion into the cannabis market.
Financials
General Finance Corporation Declares Dividend of $2.30 Per Share on Its 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock
PASADENA, Calif., Jan 17, 2018 –General Finance Corporation (NASDAQ: GFN) a leading specialty rental services company offering portable storage, modular space and liquid containment solutions (the “Company”), announced today that in accordance with the terms […]
Executive Resources
Capital
Investor Education
Binary Options: Binary Return Derivatives (ByRDs)
Bill Ryan: Introduction to Binary Options: Binary Return Derivatives (ByRDs)
Investor Presentations
McEwen Mining Inc. (NYSE: MUX) CEO Rob McEwen talks about gold market, and McEwen Mining.
McEwen Mining Inc. (NYSE: MUX) CEO Rob McEwen talks about gold market, and McEwen Mining.
Healthcare
Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
PALATINE, Ill., Jan 08, 2018 -Acura Pharmaceuticals, Inc. (OTC QB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx(TM) excess oral […]